TY - JOUR
T1 - MRI-guided Pelvic Radiation Therapy: A Primer for Radiologists
AU - Zhong, Jim
AU - Kobus, Marta
AU - Maitre, Priyamvada
AU - Datta, Anubhav
AU - Eccles, Cynthia
AU - Dubec, Michael
AU - McHugh, Damien
AU - Buckley, David
AU - Scarsbrook, Andrew
AU - Hoskin, Peter
AU - Henry, Ann
AU - Choudhury, Ananya
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Radiation therapy (RT) is a core pillar of oncologic treat-ment, and half of all patients with cancer receive this therapy as a curative or palliative treatment. The recent integration of MRI into the RT workflow has led to the advent of MRI-guided RT (MRIgRT). Using MRI rather than CT has clear advantages for guiding RT to pelvic tumors, including superior soft-tissue con-trast, improved organ motion visualization, and the potential to image tumor phenotypic characteristics to identify the most aggressive or treatment-resistant areas, which can be targeted with a more focal higher radiation dose. Radiologists should be familiar with the potential uses of MRI in planning pelvic RT; the various RT techniques used, such as brachytherapy and external beam RT; and the impact of MRIgRT on treatment paradigms. Current clinical experience with and the evidence base for MRIgRT in the settings of prostate, cervical, and bladder cancer are discussed, and examples of treated cases are illustrated. In addition, the benefits of MRIgRT, such as real-time online adaptation of RT (during treatment) and interfraction and/ or intrafraction adaptation to organ motion, as well as how MRIgRT can decrease toxic effects and improve oncologic outcomes, are highlighted. MRIgRT is partic-ularly beneficial for treating mobile pelvic structures, and real-time adaptive RT for tumors can be achieved by using advanced MRI-guided linear accelerator systems to spare organs at risk. Future opportunities for development of biologically driven adapted RT with use of functional MRI sequences and radiogenomic approaches also are outlined.
AB - Radiation therapy (RT) is a core pillar of oncologic treat-ment, and half of all patients with cancer receive this therapy as a curative or palliative treatment. The recent integration of MRI into the RT workflow has led to the advent of MRI-guided RT (MRIgRT). Using MRI rather than CT has clear advantages for guiding RT to pelvic tumors, including superior soft-tissue con-trast, improved organ motion visualization, and the potential to image tumor phenotypic characteristics to identify the most aggressive or treatment-resistant areas, which can be targeted with a more focal higher radiation dose. Radiologists should be familiar with the potential uses of MRI in planning pelvic RT; the various RT techniques used, such as brachytherapy and external beam RT; and the impact of MRIgRT on treatment paradigms. Current clinical experience with and the evidence base for MRIgRT in the settings of prostate, cervical, and bladder cancer are discussed, and examples of treated cases are illustrated. In addition, the benefits of MRIgRT, such as real-time online adaptation of RT (during treatment) and interfraction and/ or intrafraction adaptation to organ motion, as well as how MRIgRT can decrease toxic effects and improve oncologic outcomes, are highlighted. MRIgRT is partic-ularly beneficial for treating mobile pelvic structures, and real-time adaptive RT for tumors can be achieved by using advanced MRI-guided linear accelerator systems to spare organs at risk. Future opportunities for development of biologically driven adapted RT with use of functional MRI sequences and radiogenomic approaches also are outlined.
UR - http://www.scopus.com/inward/record.url?scp=85173359063&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/7eecadc4-7f20-311f-9fb0-418a4752120b/
U2 - 10.1148/rg.230052
DO - 10.1148/rg.230052
M3 - Article
SN - 0271-5333
VL - 43
JO - Radiographics
JF - Radiographics
IS - 11
M1 - e230052
ER -